A-SKIN Nederland BV
De Boelelaan 1117
1081 HV Amsterdam
Website A-SKIN Nederland BV
E-mail A-SKIN Nederland BV
T +31 (0)20 444 26 24
F +31 (0)20 444 29 64

Employees in Amsterdam: 6
Employees in R&D: 3
Year of foundation: 2006

Company Profile

A-SKIN Nederland BV is a start-up from VUmc Amsterdam, and is positioned as a tissue engineering service company developing and commercialising autologous skin products from her GMP skin culture laboratory. Current customers are located in hospitals, out-patient clinics and (long term) care facilities in the Netherlands. In the coming years the patented A-SKIN autologous skin culture technique and related products will be made available trough out-licensing and daughter companies in other European countries and beyond.
With Tiscover® A-SKIN Nederland BV offers patients and professionals a novel and superior product for healing chronic, inert skin wounds. This product fills an unmet medical need in the treatment of various skin ulcers such as due to decubitus, diabetes or vascular malfunctioning.

Science and Technologies or Services

Alliances

• VU medical centre, Amsterdam
• Euro Skin Bank, Beverwijk
• Brandwonden centrum, Beverwijk

Keywords

• Tissue culturing
• Biomaterials
• Skin wounds
• Chronic leg ulcers
• Venous leg ulcers
• Decubitus ulcers
• Diabetic ulcers
  
  

P.O.Box 587
3440 AN Woerden
Website
E-mail
T +31 (0)6 5397 8750

Employees: 1
Employees in R&D: 1
Year of foundation: 2011

Company Profile

Abundnz is a privately owned spin-off company from Ducares, a TNO company. It was founded in October 2011. Abundnz offers advanced analytical support for biotechnology and diagnostics industries and life science research worldwide. With the use of mass spectrometry, we characterize innovative medicines like peptide and protein drugs, oligonucleotides and targeted drug delivery systems and we discover and validate biomarkers. Abundnz has a unique technology to determine the clearance profile of innovative medicines in an early phase of drug development.

Science and Technologies or Services

Abundnz has a service portfolio consisting of various analytical techniques and methods. Mass spectrometry and pAMS are our core technologies. With these techniques we contribute to innovative drug development, diagnostics and life sciences research.

Alliances

Biotech companies, universities

Keywords

• mass spectrometry
• innovative medicines
• protein drugs
• peptides
• oligonucleotides
• targeted drug delivery

Academic Medical Center (AMC)
Meibergdreef 9
1105 AZ Amsterdam
Website Academic Medical Center
E-mail Amsterdam Medical Center
T +31 (0)20 566 50 56
F +31 (0)20 566 91 68

Employees in Amsterdam: 6,500
Employees in R&D: 1,400
Year of foundation: 1983

Company Profile

Science and Technologies or Services

AMC is active in the following research fields:

• Cardiovascular Diseases
• Gastr-intestinal diseases
• Immunity and Infections
• Metabolic Disorders
• Neurologic and Psychiatric Disorders
• Oncology
• Public Health and Epidemiology

AMC also offers advanced facilities and highly qualified personnel in the areas of gene and cell therapies, viral vector production, genomics, proteomics, metabolomics, bioinformatics, imaging, and animal models.

Alliances

AMC spin-offs:

• AIMM Therapeutics
• AMCAS
• Amsterdam Molecular Therapeutics (AMT)
• Arthrogen
• Hep-Art Medical Devices
• IATEC
• Macrozyme
• MicroVision Medical
• Primagen
• Valletta Health

Keywords

• Academic hospital
• Medical research
• License opportunities
• Spin-off companies
  

Aescap Venture
Strawinskylaan 1525
1077 XX Amsterdam
Website
e-mail
T +31 (0)20 570 29 40
F +31 (0)20 673 78 46

Employees in Amsterdam: 11
Employees in R&D: 0
Year of foundation: 2006

Company Profile

Aescap Venture is a venture capital company investing in private medical companies in Europe. Aescap Venture has a long-term investment horizon and invests in high-potential companies. This involves investments in all phases of development with an emphasis on earlier stages. Aescap Venture’s added value is based on a multi-disciplinary team of experienced investment partners with proven track records of success and the skills to coach entrepreneurs in accelerating the growth of their companies.

Science and Technologies or Services

At Aescap Venture, people are our greatest asset. Our partners have extensive experience and proven performance to help create successful businesses. As a result of our focus and dedication in the medical market we fully understand the opportunities and threats within this challenging arena.

Keywords

• Venture Capital
• Medical companies
• Life sciences
• Hands-on approach

Agendia B.V.
Science Park 406
1098 XH Amsterdam
Website Agendia B.V. 
E-mail Agendia B.V.
Promotion video Agendia
T +31 (0)20 462 15 00
F +31 (0)20 462 15 05

Employees in Amsterdam: 65
Employees in R&D: 9
Year of foundation: 2003

Company Profile

Agendia is committed to improving the quality of life of people suffering from cancer. The company is a world leader in gene expression analysis-based diagnostics and has developed a series of validated, state of the art tests using tumor gene expression profiling. The tests help oncologists make the right decision regarding the treatment of the individual cancer patient. Agendia was the first company to commercialise a prognostic test, MammaPrint, which predicts the risk of breast cancer recurrence. MammaPrint was cleared by the US Food and Drugs administration in February 2007.
Agendia was founded in 2003 by Netherlands Cancer Institute (NKI) researchers Laura van 't Veer, René Bernards and Bernhard Sixt and is located in Amsterdam in the Netherlands. Agendia is now in the market with three products: MammaPrint, CupPrint and DiscoverPrint.

Science and Technologies or Services

Agendia has developed high-quality diagnostic methods using microarray gene expression profiling to determine tumor specific properties. Our in vitro diagnostic laboratory services offered to physicians and pharmaceutical companies improve the accuracy of metastasis risk prediction, disease origin, targeted drug development or pre-selection of patients eligible for clinical trials.

Alliances

• Netherlands Cancer Institute

Keywords

• Gene expression analysis
• Genomic profiling
• Microarray
• Cancer
• Diagnostic
• MammaPrint
• CupPrint
• DiscoverPrint
  
  

AIMM Therapeutics B.V.
Meibergdreef 45
1105 BA Amsterdam
Website AIMM Therapeutics B.V.
E-mail AIMM Terapeutics B.V.
T +31 (0)20 566 26 48
F +31 (0)20 566 91 58

Employees in Amsterdam: 5
Employees in R&D: 5
Year of foundation: 2005

Company Profile

AIMM’s portfolio is based on proprietary platform technologies for directed, fast and efficient development of fully human monoclonal antibodies. Many innovative products for a wide range of viral and bacterial diseases as well as for cancer, are being developed.

Science and Technologies or Services

The goal is to isolate antibody-producing B cells from humans that have resolved a pathogenic challenge with high or exceptional efficiency. This would allow for the direct isolation of monoclonal antibodies with proven effectiveness in a clinical setting. Such proprietary B cell immortalization technologies for the selective isolation of human B cells shall lead to antibodies with desirable specificities.

Alliances

• AMC-Amsterdam;
• UMCU-Utrecht;
• NVI-Bilthoven.

Keywords

• Human antibodies;
• Vaccines.

Alan Turing Institute
Louis Armstrongweg 84
1311 RL Almere
Website
E-mail
T +31 (0)36 5345985

Employees: 15
Employees in R&D: 9
Year of foundation: 2009

Company Profile

The Alan Turing Institute is dedicated to innovative scientific research and education. We reiterate that we aim at an interdisciplinary approach to health-related research, particularly targeted at individualized disease treatment. We have experts in the fields of Artificial Intelligence, Obesity, Female Sexual Dysfunction, Cognitive and Affective neuroscience. We aim for the further development of our multidisciplinary research method through collaboration with external parties working in the medical domain, in cooperation with universities to safeguard and corroborate the institute's academic status and ambition.

Science and Technologies or Services

Although there is a growing interest for the individual patient in health care and health science in general, our approach is unique in that it employs techniques from artificial intelligence, and agent technology in particular, to reach its goals. In particular, knowledge from sources as heterogeneous as medicine, biology, psychology and psychiatry may each be represented by their own agents and agents may each have their own method of reasoning. Based on information available about a patient and the agents' own instruction sets, agents can reason on chains of causes and effects. In other words: our knowledge based systems structure knowledge and can reason with this knowledge in such a way that we can make more refined diagnoses and can predict prevention and treatment for individual patients based on their unique constellation.

Alliances

• Emotional Brain BV
• UvA
• UU
• Child Obesity Clinic (Almere)

Keywords

• Obesity
• Female Sexual Dysfunction
• Artificial Intelligence
• Multi Agent Systems
• Cognitive Reserve

AM-Pharma B.V.
Rumpsterweg 6
3981 AK Bunnik
Website AM-Pharma B.V.
E-mail AM-pharma B.V.
T +31 (0)30 228 92 22
F +31 (0)30 228 92 20

Employees in Amsterdam: 17
Employees in R&D: 17
Year of foundation: 2000

Company Profile

AM-Pharma is a biopharmaceutical company, based in Bunnik, The Netherlands. The company is focused on the pre-clinical and clinical development of novel therapeutics to treat inflammatory diseases and infectious diseases. All our products address high medical needs and commercially attractive markets.
Our products are based on endogenous proteins and (protein derived) peptides, optimised to fight inflammatory diseases and infections. AM-Pharma has intellectual property around two scientific platforms:

• Enhancing Toll Like Receptor mediated activation of innate immune cells
• Dephosphorylation of extracellular substrates to influence disease processes

So far, AM-Pharma has developed two products originating from its intellectual property franchise, Alkaline Phosphatase and hLF1-11 up to the point of initial proof of clinical efficacy and safety.
AM-Pharma currently employs 17 people. We out-source all non-core know how dependent development work to specialist third party organisations.
Once our products have shown to be safe and effective in patients we out-license our products to collaboration partners who become responsible for further development and worldwide marketing.

Science and Technologies or Services

Alkaline Phosphatase (AP) (acute renal failure and ulcerative colitis)
The endogenous enzyme alkaline phosphatase is expressed in various tissues throughout the human body including kidney and GI tract. AP has been shown to dephosphorylate LPS to a non-toxic form that acts as a partial antagonist on the LPS receptor complex. In addition to LPS, AP can dephosphorylate different other substrates e.g. ATP and through this dephosphorylation interfere with inflammatory response and associated tissue damage. Proof of concept has been shown in Phase IIa Proof Of Concept trials in Acute Renal Failure and Ulcerative Colitis.

HLF 1-11 Anti microbial peptide
The antimicrobial peptide hLF1-11 comprises the first 11 N-terminal amino acids of the endogenous protein; human lactoferrin. The compound exerts both antibacterial and antifungal activity against a broad range of microorganisms. Moreover, it appears that hLF1-11 has a low propensity to generate resistance in microorganisms, because it acts by stimulating the innate immune system. Phase IIa Proof Of Concept trials have are in preparation in MRSA infections and systemic Candida infections.

Keywords

• Acute Renal Failure
• Ulcerative Colitis
• MRSA
• Systemic candida infection
• Phase II clinical development
• Anti-infective
• Anti-inflammatory
  

Amdix B.V. Meibergdreef 45 1105 BA Amsterdam T +31 6 1723 6959 Website Employees in Amsterdam: 1 Employees in R&D: 0 Year of foundation: 2010

Company Profile

Amdix BV is a spin-off company of the Academic Medical Ceneter Amsterdam, focussed on the development and sales of diagnostic products.

Science and Technologies or Services

Alliances

Keywords

Arthrogen B.V.
Meibergdreef 45
1105 BA Amsterdam
Website Arthrogen B.V.
E-mail Arthrogen B.V.
T +31 (0)20 566 26 48
F +31 (0)20 566 91 68

Employees in Amsterdam: 10
Employees in R&D: 9
Year of foundation: 2005

Company Profile

Arthrogen was founded in 2005 as a joint venture of the Academic Medical Center (AMC, Amsterdam, The Netherlands) and the Dubai Bones and Joints Hospital for the clinical and commercial development of an innovative gene therapy approach, developed by researchers of the AMC, as a cure for rheumatoid arthritis locally in the joints. The lead compound will enter phase-I trials in two years.

Science and Technologies or Services

Development of local gene therapy targeting TNF might provide a novel method to treat isolated arthritis activity. This could lead to the development of novel therapeutic strategies targeting primarily the site of inflammation and prevent joint destruction. The gene delivery approach, in addition to other therapeutics, may ultimately provide a more comprehensive treatment for the management of RA. Obviously, achievement of this goal will have a substantial beneficial effect on the RA patient and ultimately on society. Arthrogen aims to develop several innovative medical strategies using gene therapy for local treatment of RA, using several types of cytokines.

Alliances

• Dubai Bones and Joints Center
• Academisch Medisch Centrum Amsterdam
• Galapagos BV
• Agendia BV

Keywords

• Rheumatoid arthritis
• Gene therapy
• Local administration
• Cytokines
  
  
  

Piet Heinkade 183
1019 HC Amsterdam
Website
E-mail
T +31 (0)88 650 6500
F +31 (0)88 650 6555

Employees: 3
Employees in R&D: 0
Year of foundation: 2011

Company Profile

We focus entirely on the life sciences, together we have over 20 years of experience in the life science sector both as attorney at law and as in-house counsel.

Keywords

• law
• legal services
• coaching of high tech and life sciences start-up and spin-out companies

Bluelarix Designworks
Willem Fenengastraat 2W
1096 BN Amsterdam
Website Bluelarix Designworks 
E-mail Bluelarix Designworks
T +31 (0)20 820 22 11
F +31 (0)20 820 22 12

Employees in Amsterdam: 5
Employees in R&D: 5
Year of foundation: 2007

Company Profile

We specialize in designing products that make our lives safer, more interesting and easier. Our designs are logical, emotional, outspoken, simple and truely innovative.

Science and Technologies or Services

Medical product design, interaction design, engineering and product development services

Alliances

We work together with specialized electronics production companies with certifications for production and assembly of medical devices. We work together with hospitals and dokters in projects.

Keywords

• Medical design
• Product design
• interaction design
• Product development
• Electronics development
  

Bmeye B.V.
AMC, Suite K2-245
Meibergdreef 9
1105 AZ Amsterdam
Website Bmeye
E-mail Bmeye
Promotion video Bmeye
T +31 (0)20 566 58 38
F +31 (0)20 697 64 24

Employees in Amsterdam: 14
Employees in R&D: 8
Year of foundation: 2005

Company Profile

BMEYE is a technology-based company that develops innovative medical devices for the continuous non-invasive monitoring of blood pressure and cardiovascular hemodynamics.
Based on decades of fundamental technology and sensor research, BMEYE is committed to provide researchers, clinicians and patients worldwide with precise, robust, easy-to-use solutions for continuous, entirely non-invasive, cardiovascular monitoring
BMEYE Nexfin®monitors are designed for patient safety first: all measurements are completely non-invasive, with continuous data, no events are missed and with using our comfortable finger sensor, no needles, catheters or injections are needed. The precision of the Nexfin® sophisticated and robust methods provides a full hemodynamic profile with real-time data posted within a minute.

Science and Technologies or Services

Easy diagnosis, effective treatment
Patient responses to diagnostic cardiovascular tests, to interventional devices like pacemakers and to pharmacological treatment with drugs are highly variable and unpredictable, and are often composed of dynamic changes in blood pressure, vascular resistance, stroke volume and cardiac output. Today, their assessment is based on ECG measurements and intermittent standard upper arm NIBP cuff data that misses most if not all of the dynamics of the response.
Integrated continuous measurement of blood pressure and cardiac output in the BMEYE Nexfin® device allows easy and accurate diagnosis and effective follow-up of treatment, and provides the opportunity for immediate feedback to the patient on the effects of therapy and treatment.

Early warning, early and effective response
Patient response to anesthetic agents, cardiovascular drugs and surgical intervention is highly variable and unpredictable, and their combination often induces significant and rapid changes in blood pressure and cardiac output. During surgery, blood pressure monitoring, with the exception of less than 12% of patients who get direct intra-arterial blood pressure monitoring, is accomplished by using a standard cuff-based NIBP monitor, providing only intermittent measurements every 3-5 minutes. Cardiac output monitoring is even absent except in less than  4% of patients who receive pulmonary artery catheter CO monitoring.
Integrated continuous measurement of blood pressure and cardiac output allows early recognition and treatment of rapid changes in hemodynamics (where cardiac output changes usually lead blood pressure changes siginicantly in time) and provides immediate feedback on the impact of interventions for optimal patient management.

Unlike invasive A-lines and PA catheters, which carry a risk of infection or other complications, the BMEYE Nexfin® devices provide an integrated non-invasive solution for continuous blood pressure and cardiac output monitoring. In the OR today, blood pressure and cardiac output are the only critical parameters that are not monitored continuously on all patients. Heart rate, respiration and oxygenation are all monitored continuously and non-invasively for patient safety. The BMEYE Nexfin® technology allows truly complete, integrated and continuous non-invasive vital signs safety monitoring in all patients.

Alliances

• AMC, Amsterdam
• Mayo Clinic, Rochester, MN, USA

Keywords

• Cardiovascular
• Hemodynamics
• Patient Monitoring
• Noninvasive
• Continuous
• Safe
• Precise
• Easy-to-use
• Blood Pressure
• Cardiac Output

Zernikedreef 11
2333 CK Leiden
Website
E-mail
T +31 (0)71 518 8743
F +31 (0)71 518 8415

Employees: 6
Employees in R&D: 0
Year of foundation: 2007

Company Profile

CBD is a non-profit organization staffed by a small, dedicated group of lecturers affiliated to the Faculty of Technology in the University of Applied Sciences Leiden (Hogeschool Leiden). We possess a track record in successful postgraduate education of technical lab personnel, spanning over 20 years. Our main focus is to strengthen and modernize the theoretical and practical knowledge base of technical personnel involved in laboratory work in health care, pharmaceutical, industrial and forensic settings, thereby providing a secure basis for quality improvement. We also provide consultancy services for clients seeking to optimize lab tests and boost their quality assurance procedures.
Organisations who chose CBD for their schooling and training needs include VUmc, Crucell, Philips Healthcare Incubator, UMC Groningen, Naktuinbouw, Radboud University Medical Center, Vitens, Erasmus Medical Center and Heineken.

Science and Technologies or Services

CBD is active in the following areas of life science training and consultancy:

• Molecular biology/molecular diagnostics
• Microbiology/infectious diseases
• Immunology and immunochemistry
• Clinical chemistry and hematology
• Histology/pathology
• Agriculture/horticulture

CBD offers

• training courses for groups or individuals (at the University of Applied Sciences Leiden)
• incompany training trajectories, in which the course content is tailored to fit the schooling and quality improvement needs of the client
• consultancy services
• organization of conferences.

Alliances

• Toplab @ Hogeschool Leiden
• Naktuinbouw
• Boerhaave Nascholing, LUMC
• Symbiant

Keywords

• University of Applied Sciences Leiden
• life sciences
• postgraduate professional education
• in company training
• consultancy
• molecular biology/ molecular diagnostics
• microbiology/ infectious diseases
• immunology and immunochemistry
• clinical chemistry and hematology
• histology / pathology
• agriculture / horticulture

Clinical Reach Drug Development b.v.
Zoeterwoudseweg 74
2321 GP Leiden
Website Clinical Reach
E-mail Clinical Reach
T +31 (0)71 531 18 52

Employees in Amsterdam: 1
Employees in R&D: 1
Year of foundation: 2009 

Company Profile

Clinical Reach is an independent company that aims to be a partner in your development team, from the strategic level down to the level of hands-on support in the execution of individual studies.

Company Profile

We join you in your goal to develop a product that meets regulatory expectations and that will be commercially successful. Pending your needs, we support you in your efforts to:

• Define the target product profile. 
•  Define the development plan that brings you to that target. 
•  Seek key opinion leader and regulatory authority challenge of the target product profile and development plan. 
•  Design the individual studies in your development plan. 
•  Identify the appropriate contract research organization to execute your studies, and work with this external partner on a day-to-day basis until the study has been reported. 
•  Present your plans and data to external parties, including investors, potential licensing partners and regulatory agencies.

Alliances

We are informally associated with various expert companies and individual experts providing services complementary to those of Clinical Reach, including:

• Regulatory services. 
•  Pharmaceutical development and clinical trial material production, packaging and labeling.
• Clinical study execution and management services. 
•  Recording and reporting of electronic patient-reported outcome (ePRO) data. 
•  Bioanalytical services, including biomarker assays and immunogenicity assessments. 
•  Pharmacokinetic and –dynamic data analysis. 
•  Modeling and simulation from clinical trial design to kinetic and dynamic data. 
•  Data management and statistics. 
•  Medical writing.

Keywords

• Target product profile
• drug development
• regulatory challenge
• key opinion leader challenge
• study design and execution